TY - JOUR
T1 - Smoking duration, intensity, and risk of Parkinson disease
AU - Chen, H.
AU - Huang, X.
AU - Guo, X.
AU - Mailman, R. B.
AU - Park, Y.
AU - Kamel, F.
AU - Umbach, D. M.
AU - Xu, Q.
AU - Hollenbeck, A.
AU - Schatzkin, A.
AU - Blair, A.
N1 - Funding Information:
Dr. Chen receives NIH intramural funding (Z01-ES-101986) and serves on the editorial board of the International Journal of Molecular Epidemiology and Genetics. Dr. Huang has served as a consultant for Easton Associate, Public Healthcare, Teva Pharmaceutical Industries Ltd., and the National Institute of Environmental Health Sciences; holds patent US 6,916,823 (issued 2005): Method of treatment of dopamine-related dysfunction (plus foreign patents) and has filed a patent regarding Early detection of Parkinson's disease using novel motor signs; has received honoraria for speaking and education activities not sponsored by industry; receives research support from the NIH/NINDS (NS060722 [PI]), the Pennsylvania Tobacco Settlement Fund and from Huck Institute of Penn State University; and holds stock in BioValve Technologies, Inc. Dr. Guo reports no disclosures. Dr. Mailman serves on the editorial boards of the Journal of Molecular and Biochemical Toxicology and Current Opinion in Central and Peripheral Nervous System (CPNS) Drugs; receives royalties from the publication of Introduction to Biochemical and Molecular Toxicology, 4th ed. (Wiley, 2001); has received speaker honoraria from activities not sponsored by industry; serves as a consultant for Roche; receives research support from the NIH (U19 MH082441-01 [Penn State PI Project] and NS042402 [Co-PI]), the Pennsylvania Tobacco Settlement Fund, the Keystone Fund, and from the Commonwealth of Pennsylvania Ben Franklin Technology Development Authority; holds stock in Effipharma Inc. and BioValve Technologies, Inc.; has served as an expert witness in cases involving Eli Lilly and Company and Barr Laboratories, Inc.; holds the following patents (plus foreign patents on each): US 5,420,134 (issued 1995): Substituted hexahydrobenzo[a] phenanthridines; US 5,959,110 (issued 1999): Fused isoquinolines as dopamine receptor ligands; US 6,194,423 (issued 2001): Fused isoquinolines as dopamine receptor ligands; US 6,413,977 (issued 2002): Chromeno [4,3,2-DE]isoquinolines as potent dopamine receptor ligands; US 6,916,823 (issued 2005): Method of treatment of dopamine-related dysfunction; US 6,916,832 (issued 2005): Chromeno [4,3,2-DE] isoquinolines as potent dopamine receptor ligands; and has filed additional patent applications regarding: Dopamine agonists with improved pharmacokinetic properties, Method of administration of dopamine receptor agonists; and Co-administration of dopamine-receptor binding compounds. Dr. Park reports no disclosures. Dr. Kamel serves as an Associate Editor of Environmental Health Perspectives and on the editorial board of the American Journal of Epidemiology; and receives intramural research funding from the NIH/NIEHS. Dr. Umbach and Dr. Xu report no disclosures. Dr. Hollenbeck serves on the Scientific Advisory Committee of the Love/Avon Army of Women; and is a full-time salaried employee of AARP. Dr. Schatzkin is an employee of the NIH National Cancer Institute and serves as Principal Investigator of the NIH-AARP Diet and Health Study. Dr. Blair is a Scientist Emeritus at the National Cancer Institute and serves on the editorial advisory boards of the Scandinavian Journal of Work Environment and Health, the American Journal of Industrial Medicine, and the Journal of Agricultural Safety and Health. He also served as the Interim Director of the Occupational Cancer Research Centre in Toronto, ON, Canada.
Funding Information:
Study funding: Supported by the intramural research program of the NIH, the National Institute of Environmental Health Sciences (Z01-ES-101986) , and the National Cancer Institute (Z01 CP010196-02) .
PY - 2010/3/16
Y1 - 2010/3/16
N2 - Objective: To evaluate the relative importance of smoking duration vs intensity in reducing the risk of Parkinson disease (PD). Methods: The study included 305,468 participants of the NIH-AARP Diet and Health cohort, of whom 1,662 had a PD diagnosis after 1995. We estimated odds ratios (OR) and 95% confidence intervals from multivariate logistic regression models. Results: Compared with never smokers, the multivariate ORs were 0.78 for past smokers and 0.56 for current smokers. Among past smokers, a monotonic trend toward lower PD risk was observed for all indicators of more smoking. Stratified analyses indicated that smoking duration was associated with lower PD risk within fixed intensities of smoking. For example, compared with never smokers, the ORs among past smokers who smoked > 20 cigarettes/day were 0.96 for 1-9 years of smoking, 0.78 for 10-19 years, 0.64 for 20-29 years, and 0.59 for 30 years or more (p for trend = 0.001). In contrast, at fixed duration, the typical number of cigarettes smoked per day in general was not related to PD risk. Close examination of smoking behaviors in early life showed that patients with PD were less likely to be smokers at each age period, but if they smoked, they smoked similar numbers of cigarettes per day as individuals without PD. Conclusions: This large study suggests that long-term smoking is more important than smoking intensity in the smoking-Parkinson disease relationship.
AB - Objective: To evaluate the relative importance of smoking duration vs intensity in reducing the risk of Parkinson disease (PD). Methods: The study included 305,468 participants of the NIH-AARP Diet and Health cohort, of whom 1,662 had a PD diagnosis after 1995. We estimated odds ratios (OR) and 95% confidence intervals from multivariate logistic regression models. Results: Compared with never smokers, the multivariate ORs were 0.78 for past smokers and 0.56 for current smokers. Among past smokers, a monotonic trend toward lower PD risk was observed for all indicators of more smoking. Stratified analyses indicated that smoking duration was associated with lower PD risk within fixed intensities of smoking. For example, compared with never smokers, the ORs among past smokers who smoked > 20 cigarettes/day were 0.96 for 1-9 years of smoking, 0.78 for 10-19 years, 0.64 for 20-29 years, and 0.59 for 30 years or more (p for trend = 0.001). In contrast, at fixed duration, the typical number of cigarettes smoked per day in general was not related to PD risk. Close examination of smoking behaviors in early life showed that patients with PD were less likely to be smokers at each age period, but if they smoked, they smoked similar numbers of cigarettes per day as individuals without PD. Conclusions: This large study suggests that long-term smoking is more important than smoking intensity in the smoking-Parkinson disease relationship.
UR - http://www.scopus.com/inward/record.url?scp=77950505354&partnerID=8YFLogxK
U2 - 10.1212/WNL.0b013e3181d55f38
DO - 10.1212/WNL.0b013e3181d55f38
M3 - Article
C2 - 20220126
AN - SCOPUS:77950505354
SN - 0028-3878
VL - 74
SP - 878
EP - 884
JO - Neurology
JF - Neurology
IS - 11
ER -